Osteoporosis is a progressive, systemic, skeletal disease characterized
by decreased bone mass and microarchitectural deterioration of bone
tissue leading to increased bone fragility and susceptibility to
The more risk factors (eg history of fracture, advanced age,
comorbidities, etc) that are present, the greater the risk
A family physician (GP)-led, community screening programme helped reduce the incidence of hip fracture in older women, highlighting the important role played by GPs in reducing the morbidity associated with hip fractures in this population, the UK-based SCOOP* trial revealed.
A once-daily subcutaneous dose of teriparatide may be more effective than once-weekly oral risedronate in preventing vertebral fractures in post-menopausal women with osteoporosis and a history of vertebral fractures, findings from the VERO* trial show.
An initial strategy of 1-year romosozumab followed by alendronate is superior over alendronate alone in reducing new vertebral fractures in postmenopausal women with osteoporosis at high risk for fracture, according to the ARCH* study.
Women who temporarily or permanently stop taking bisphosphonates (drug holiday) for an extended period of time may have an increased risk of hip fractures, findings from a recent population-based study revealed.
Levels of urinary iodine concentration appear to be lower in women with postmenopausal osteoporosis than in healthy postmenopausal women, suggesting the involvement of iodine deficiency in osteoporosis in this population, according to a study.
Romosozumab, a sclerostin monoclonal antibody, increased bone mineral density (BMD) of the hip and spine over 12 months of treatment compared with teriparatide in postmenopausal women with osteoporosis who were transitioning from bisphosphonates, according to the STRUCTURE* trial.
Postmenopausal women with osteoporosis had a low incidence of fracture and a continuous increase in bone mineral density (BMD) after 7–10 years of denosumab treatment, according to results of the open-label, 7-year extension of the phase III FREEDOM* trial.
New drug applications approved by US FDA as of 16 - 30 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.